High-level cytoplasmic cyclin D1 expression in lymph node metastases from prostate cancer independently predicts early biochemical failure and death in surgically treated patients

Fleischmann, Achim; Rocha, Carla; Saxer-Sekulic, Nikolina; Zlobec, Inti; Sauter, Guido; Thalmann, George N.

doi:10.1111/j.1365-2559.2011.03800.x

Cited by 20 publications

(17 citation statements)

References 50 publications

(95 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Previous studies (6,7) have shown no relationship between cyclin D1 expression and the Gleason score, but, in this study, we found a positive statistically significant association between the Gleason score and cyclin D1 expression, with high-grade tumors displaying high cyclin D1 expression compared with low-grade tumors, in agreement with a study conducted by Emin Özbek et al (21). However, unlike our study, other studies may not have determined the optimal cut-off value using ROC curve analysis, such as the Emin Özbek study, that showed positive correlation between Gleason score and cyclin D1.…”

Section: Discussionsupporting

confidence: 93%

See 1 more Smart Citation

Cyclin D1 expression in prostate carcinoma

Pereira

Ravinal

Costa

et al. 2014

Braz J Med Biol Res

View full text Add to dashboard Cite

The purpose of this study was to investigate the relationship between cyclin D1 expression and clinicopathological parameters in patients with prostate carcinoma. We assessed cyclin D1 expression by conventional immunohistochemistry in 85 patients who underwent radical prostatectomy for prostate carcinoma and 10 normal prostate tissue samples retrieved from autopsies. We measured nuclear immunostaining in the entire tumor area and based the results on the percentage of positive tumor cells. The preoperative prostate-specific antigen (PSA) level was 8.68±5.16 ng/mL (mean±SD). Cyclin D1 staining was positive (cyclin D1 expression in >5% of tumor cells) in 64 cases (75.4%) and negative (cyclin D1 expression in ≤5% of tumor cells) in 21 cases (including 15 cases with no immunostaining). Normal prostate tissues were negative for cyclin D1. Among patients with a high-grade Gleason score (≥7), 86% of patients demonstrated cyclin D1 immunostaining of >5% (P<0.05). In the crude analysis of cyclin D1 expression, the high-grade Gleason score group showed a mean expression of 39.6%, compared to 26.9% in the low-grade Gleason score group (P<0.05). Perineural invasion tended to be associated with cyclin D1 expression (P=0.07), whereas cyclin D1 expression was not associated with PSA levels or other parameters. Our results suggest that high cyclin D1 expression could be a potential marker for tumor aggressiveness.

show abstract

Section: Discussionsupporting

confidence: 93%

“…The mean age and mean preoperative PSA levels were similar to those reported in previous studies (7,9,10). The predominant pathological TNM stage was pT2c (60%), but this was different from previous studies by Freedland et al (11) (pT2a, 34%) and Makarov et al (12) (pT1c, 77%).…”

Section: Discussionsupporting

confidence: 88%

Cyclin D1 expression in prostate carcinoma

Pereira

Ravinal

Costa

et al. 2014

Braz J Med Biol Res

View full text Add to dashboard Cite

show abstract

“…Molecular parameters that have been described to be linked to metastasis and cancer-related death in patient cohorts describing at least 100 patients with unfavorable events include p53 (41,42), bcl-2 (41), microvessel density (41), Ki-67 (42), CD10 (43), cyclin D1 (44), telomere length (45), HER2-neu (46), Stat5a/b (47), AMACR (48), HSP-27 (49), and MDM2 (42). All these parameters have also been linked to PSA recurrence in the respective studies (44,(46)(47)(48).…”

Section: Discussionmentioning

confidence: 99%

The Combination of DNA Ploidy Status and PTEN/6q15 Deletions Provides Strong and Independent Prognostic Information in Prostate Cancer

Lennartz

Minner

Brasch

et al. 2016

Clinical Cancer Research

Self Cite

View full text Add to dashboard Cite

show abstract

“…Cyclin D1 is one of the key regulators in the control of cell cycle progression from G0-G1 to S phase, and inducible Cyclin D1 forms a complex with CDK4/6, which phosphorylates the retinoblastoma tumor suppressor protein (33), sequestrates pRb growth inhibitory effects on E2F and enables E2F transcription factors to transcriptional regulate genes required for entry into the DNA synthetic phase (S) of the cell division cycle (34). Cyclin D1 overexpression prevails over that of Cyclin D2 and D3 (35), and overexpression of Cyclin D1 is one of the cancer features and is responsible for inducing excessive cellular proliferation in many human cancers, including bladder cancer (4), breast (36), cervix (37), colon (38), prostate (39), and skin cancer (40). Thus, Cyclin D1 is one of the most frequently altered cell cycle regulating protein in cancers and therefore, is a potential therapeutic target (41, 42).…”

Section: Discussionmentioning

confidence: 99%

Cyclin D1 Downregulation Contributes to Anticancer Effect of Isorhapontigenin on Human Bladder Cancer Cells

Fang

Cao

Hou

et al. 2013

Molecular Cancer Therapeutics

View full text Add to dashboard Cite

Isorhapontigenin (ISO) is a new derivative of stilbene compound that was isolated from the Chinese herb Gnetum Cleistostachyum, and has been used for treatment of bladder cancers for centuries. In our current studies, we have explored the potential inhibitory effect and molecular mechanisms underlying ISO anti-cancer effects on anchorage-independent growth of human bladder cancer cell lines. We found that ISO showed a significant inhibitory effect on human bladder cancer cell growth and was accompanied with related cell cycle G0/G1 arrest as well as downregulation of Cyclin D1 expression at the transcriptional level in UMUC3 and RT112 cells. Further studies identified that ISO down-regulated Cyclin D1 gene transcription via inhibition of SP1 transactivation. Moreover, ectopic expression of GFP-Cyclin D1 rendered UMUC3 cells resistant to induction of cell cycle G0/G1 arrest and inhibition of cancer cell anchorage-independent growth by ISO treatment. Together, our studies demonstrate that ISO is an active compound that mediates for Gnetum Cleistostachyum’s induction of cell cycle G0/G1 arrest and inhibition of cancer cell anchorage-independent growth through down-regulating SP1/Cyclin D1 axis in bladder cancer cells. Our studies provide a novel insight into understanding the anti-cancer activity of the Chinese herb Gnetum Cleistostachyum and its isolate ISO.

show abstract

High-level cytoplasmic cyclin D1 expression in lymph node metastases from prostate cancer independently predicts early biochemical failure and death in surgically treated patients

Abstract: The subcellular location of cyclin D1 expression in prostate cancer is linked to specific clinical courses. Survival stratification according to biomarker expression in metastases indicates an important role for tumour sampling from these tissues.

Cited by 20 publications

References 50 publications

Cyclin D1 expression in prostate carcinoma

Cyclin D1 expression in prostate carcinoma

The Combination of DNA Ploidy Status and PTEN/6q15 Deletions Provides Strong and Independent Prognostic Information in Prostate Cancer

Cyclin D1 Downregulation Contributes to Anticancer Effect of Isorhapontigenin on Human Bladder Cancer Cells

Contact Info

Product

Resources

About